These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29513759)

  • 21. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
    Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
    Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
    BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
    Burger JA; Sivina M; Jain N; Kim E; Kadia T; Estrov Z; Nogueras-Gonzalez GM; Huang X; Jorgensen J; Li J; Cheng M; Clow F; Ohanian M; Andreeff M; Mathew T; Thompson P; Kantarjian H; O'Brien S; Wierda WG; Ferrajoli A; Keating MJ
    Blood; 2019 Mar; 133(10):1011-1019. PubMed ID: 30530801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic factors for chronic lymphocytic leukemia with typical and atypical immunophenotype].
    Cao X; Xu W; Wu YJ; Qiao C; Liu Q; Fan L; Miao KR; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jul; 30(7):450-3. PubMed ID: 19954596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.
    Molica S; De Rossi G; Luciani M; Levato D
    Haematologica; 1995; 80(2):176-93. PubMed ID: 7628755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
    Lin KI; Tam CS; Keating MJ; Wierda WG; O'Brien S; Lerner S; Coombes KR; Schlette E; Ferrajoli A; Barron LL; Kipps TJ; Rassenti L; Faderl S; Kantarjian H; Abruzzo LV
    Blood; 2009 Apr; 113(14):3168-71. PubMed ID: 19050308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
    Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia.
    Miao Y; Fan L; Wu YJ; Xia Y; Qiao C; Wang Y; Wang L; Hong M; Zhu HY; Xu W; Li JY
    Oncotarget; 2016 Mar; 7(12):13551-62. PubMed ID: 26910908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
    Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
    Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic significance of telomere length in patients with chronic lymphocytic leukemia].
    Hou YQ; Xu W; Miao KR; Qiao C; Zhu HY; Zhu DX; Zhuang Y; Wu YJ; Wang JN; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):570-4. PubMed ID: 20561403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production.
    Lagneaux L; Delforge A; Dorval C; Bron D; Stryckmans P
    Blood; 1993 Oct; 82(8):2379-85. PubMed ID: 7691258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
    Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
    Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
    Izutsu K; Kinoshita T; Takizawa J; Fukuhara S; Yamamoto G; Ohashi Y; Suzumiya J; Tobinai K
    Jpn J Clin Oncol; 2021 Mar; 51(3):408-415. PubMed ID: 33244584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
    Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
    Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.